About Melanoma-associated antigen C2
Melanoma-associated antigen C2 (MAGEC2) is a protein
from Homo sapiens identified by UniProt accession
Q9UBF1, 373 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Melanoma-associated antigen C2 |
|---|
| UniProt accession | Q9UBF1 |
|---|
| Gene | MAGEC2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 373 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (71)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.11
- non-small cell lung carcinoma · score 0.09
- hepatocellular carcinoma · score 0.09
- melanoma · score 0.08
- triple-negative breast cancer · score 0.08
- pachyonychia congenita · score 0.07
- cancer · score 0.04
- Miyoshi myopathy · score 0.04
- breast ductal carcinoma in situ · score 0.03
- mucosal melanoma · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBF1-F1 | alphafold | PREDICTED | 65.11 | — |
Amino-acid sequence (373 residues)
MPPVPGVPFR NVDNDSPTSV ELEDWVDAQH PTDEEEEEAS SASSTLYLVF SPSSFSTSSS LILGGPEEEE VPSGVIPNLT ESIPSSPPQG PPQGPSQSPL SSCCSSFSWS SFSEESSSQK GEDTGTCQGL PDSESSFTYT LDEKVAELVE FLLLKYEAEE PVTEAEMLMI VIKYKDYFPV ILKRAREFME LLFGLALIEV GPDHFCVFAN TVGLTDEGSD DEGMPENSLL IIILSVIFIK GNCASEEVIW EVLNAVGVYA GREHFVYGEP RELLTKVWVQ GHYLEYREVP HSSPPYYEFL WGPRAHSESI KKKVLEFLAK LNNTVPSSFP SWYKDALKDV EERVQATIDT ADDATVMASE SLSVMSSNVS FSE
Explore Melanoma-associated antigen C2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets